Lido Advisors LLC Buys 388 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Lido Advisors LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,494 shares of the medical research company’s stock after purchasing an additional 388 shares during the period. Lido Advisors LLC’s holdings in IQVIA were worth $883,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $1,616,000. Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. bought a new stake in shares of IQVIA in the 4th quarter worth $941,000. Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS lifted its holdings in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $153.42 on Friday. The firm’s 50 day simple moving average is $167.52 and its two-hundred day simple moving average is $191.06. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $27.05 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. decreased their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a report on Thursday, April 10th. UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.